Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

23.20
-0.9600-3.97%
Post-market: 23.750.5500+2.37%19:30 EDT
Volume:1.55M
Turnover:35.94M
Market Cap:2.77B
PE:-10.82
High:24.75
Open:24.60
Low:22.67
Close:24.16
52wk High:42.21
52wk Low:21.02
Shares:119.54M
Float Shares:90.76M
Volume Ratio:0.95
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1442
EPS(LYR):-1.7211
ROE:-36.81%
ROA:-20.11%
PB:4.39
PE(LYR):-13.48

Loading ...

Newamsterdam Pharma to Present Obicetrapib Data for Early Alzheimer’s Prevention at AAIC 2026

Reuters
·
Jul 01

NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says

MT Newswires Live
·
Jun 30

RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jun 30

Newamsterdam Pharma Chief Accounting Officer Louise Kooij Sells USD 1.21 Million in Shares

Reuters
·
Jun 25

NewAmsterdam Pharma posts real-world study presentation on high-intensity statin intolerance, adverse events

Reuters
·
Jun 17

Did Druckenmiller’s Spotlight and ESOP Shelf Just Reframe NewAmsterdam Pharma’s (NAMS) Obicetrapib Story?

Simply Wall St.
·
Jun 09

NewAmsterdam Pharma to present obicetrapib data at National Lipid Association Scientific Sessions

Reuters
·
Jun 03

NewAmsterdam Pharma shareholders approve 2026 employee stock purchase plan at annual meeting

Reuters
·
Jun 03

NewAmsterdam Pharma joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

NewAmsterdam Pharma Chief Accounting Officer Louise Kooij reports $ 2.32 million share sale

Reuters
·
May 28

Why NewAmsterdam Pharma (NAMS) Is Up 29.7% After Detailing Obicetrapib Phase 3 And Launch Milestones

Simply Wall St.
·
May 11

Stock Track | NewAmsterdam Pharma Soars 5.19% Intraday on Anticipation of Upcoming Conference Presentations

Stock Track
·
May 11

Analysts Conflicted on These Healthcare Names: Treace Medical Concepts (TMCI), NewAmsterdam Pharma Company (NAMS) and LENSAR (LNSR)

TIPRANKS
·
May 11

NewAmsterdam Pharma to present at BofA Securities Health Care Conference

Reuters
·
May 11

Stock Track | NewAmsterdam Pharma Soars 5.31% Intraday on Guggenheim's Buy Rating

Stock Track
·
May 08

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 08

Guggenheim Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
May 08

NewAmsterdam Pharma Company NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

NewAmsterdam Pharma Q1 net loss widens to USD 48.4 million

Reuters
·
May 07

Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Dow Jones
·
May 07